CN1663578A - Application of liquorice glycoside in preparing drugs for preventing and/or treating depression - Google Patents
Application of liquorice glycoside in preparing drugs for preventing and/or treating depression Download PDFInfo
- Publication number
- CN1663578A CN1663578A CN 200410004768 CN200410004768A CN1663578A CN 1663578 A CN1663578 A CN 1663578A CN 200410004768 CN200410004768 CN 200410004768 CN 200410004768 A CN200410004768 A CN 200410004768A CN 1663578 A CN1663578 A CN 1663578A
- Authority
- CN
- China
- Prior art keywords
- liquirtin
- liquorice
- glycoside
- depression
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a novel use of liquorice glycoside, more specifically the use of liquorice glycoside in the preparation of medicine for preventing and/or treating depression.
Description
Technical field
The present invention relates to a kind of new purposes of liquirtin, particularly relate to liquirtin and prevent and/or treat application in the depression medicine in preparation.
Background technology
Depression is the able-bodied commonly encountered diseases of the harm whole mankind, frequently-occurring disease.Along with the quickening of modern life rhythm, its sickness rate is soaring fast.In the population of the whole world 1/3 can be suffered from depression in life at it, and WHO estimates that whole world patients with depression surpasses 300,000,000.Epidemiological study is the result show, the danger that external women suffers from depression throughout one's life is 10-25%, the male is 5-12% (Schatzberg AF, Nemeroff CB.Textbook of psychopharmacology[M] .Washington DC:American Psychiatric Press, 1995.141-193).At present, depression ranks the 4th in the disease that threatens human health, expect the year two thousand twenty, and depression will become second largest disease, be only second to heart disease.
Modern medicine study shows, depression pathogeny complexity, and induced factor is more, and clinical disease is various, often is difficult to obtain satisfactory effect at the medicine of certain single link.There are shortcomings such as the antidepressant spectrum is narrow, toxic and side effects is big mostly in synthetic antidepressants.Therefore, both at home and abroad begin to pay attention to aspect the development of antidepressant drug and the exploitation conventional medicament and natural drug (Yao Chunfang, the medicine that the red .1997 of Yun pomegranate maybe may go on the market. Chinese Journal of New Drugs, 1996,5 (1): 13; Zhang Qiuju. the Drug therapy general introduction of senile melancholia. Chinese Pharmacological circular, 1995,11 (3): 262; Zhang Chengwen. american plant extract latest tendency and development trend. external medical plant amedica fascicle, 1999,14 (1): 1; Cai Yuegang. psychotherapeutic drug. Chinese Journal of New Drugs, 1997,6 (5): 328).At present the plant amedica with antidepressant activity of American-European market listing and extract thereof comprise Herba Hyperici Monogyni (Hypericum perforatum L.) (Liu Yibing. Herba Hyperici Monogyni progress I-former plant, gather, preparation and chemical constituent. external medical plant amedica fascicle, 1998,13 (3): 99; Wheatley D.LI 160, anextract of St.John ' s wort, versus amitriptyline in mildly to moderatelydepressed outpatients a controlled 6-week clinical trial.Pharmacopsychiatry, 1997,30 (suppl.2): 77; Butterweck V, WallA, Lieflander-Wulf U, Winterhoff H, Nahrstedt A et al.Effects of the total extract and fractions of Hypericumperforatum in animal assays for antidepressant activity.Pharmacopsychiatry, 1997,30 (suppl.2): 117), Valeriana Fauriei Briq. (Valeriana fauriei) (Oshima Y, MatsuokaS.Ohizumi Y.Antidepressant principles of Valeriana fauriei Roots.Chem.Pharm.Bull., 1995,169) and Semen Ginkgo (Ginkgo biloba L.) (Wu Chunfu 43 (1):, the trip pine, Liu Wen, Xu Yongmeng, Li Fengli, Yao new life. bilobalide and Folium Ginkgo extract are to the influence of striatum and limbic system dopamine and metabolite content thereof. Chinese herbal medicine, 1995,26 (5): 253) etc., these plant amedica are light in treatment, the moderate depressive patients aspect has curative effect preferably.Also finding single Chinese medicine Radix Morindae Officinalis (Morinda officinalis How.) (Cai Bing at the research of the unfolded antidepressant effect of Chinese medicine, Cui Chengbin, Chen Yuhua, Xu Yukun, Luo Zhipu, Yang Ming, Yao Zhiwei. inulin type oligosaccharides monomer component is to the antidepressant effect of mice in the Radix Morindae Officinalis. Chinese J Pharmacol Toxicol, 1996,10 (2): 109), Semen Arecae (Areca catechu L.) (Samel D, Donnella D A, Witte D, et al.The effect of purified extract of Fagopyrumesculentum (Buckwheat) on protein kinases involved in signal transductionpathways.Planta Med, 106) etc. 1996,6 (2): have antidepressant effect.Clinically, Chinese medicine is having curative effect preferably aspect the treatment depression, and test confirms that in these compound recipes it is depressed active that classical compound recipes such as the Radix Bupleuri soothing liver-QI looses, GANMAI DAZAO TANG, lilii and Rehmanniae Decoction have anti-laboratory animal.
Liquirtin is a kind of flavonoids effective constituent in the Chinese medicine Radix Glycyrrhizae.The major function of the liquirtin of having reported at present, is antiviral, desalination melanin.
The innovation and creation content
A kind of new purposes that the purpose of this invention is to provide liquirtin.
The inventor studies show that, liquirtin has the effect that prevents and/or treats depression.
Above-mentioned liquirtin can be commercially available liquirtin, also can be prepared according to a conventional method.
When needing, in said medicine, can also add one or more pharmaceutically acceptable carriers.Described carrier comprises diluent, excipient, filler, binding agent, wetting agent, disintegrating agent, absorption enhancer, surfactant, absorption carrier, lubricant of pharmaceutical field routine etc., can also add flavouring agent, sweeting agent etc. in case of necessity.
Medicine of the present invention can be made various ways such as injection, tablet, powder, granule, capsule, oral liquid, unguentum, cream.The medicine of above-mentioned various dosage forms all can be according to the conventional method preparation of pharmaceutical field.
The consumption of said medicine is generally 1-20mg liquirtin/kg body weight/day.
In contrast test, find to give the oral liquirtin of white mice, can significantly improve mice and force dead time in swimming test and the test of outstanding tail, will in the preventing and/or treating of depression, play an important role.
The specific embodiment
Embodiment 1, the experiment of mice forced swimming
Adopt the mice depression model---forced swimming experiment (FST), concrete grammar is as follows:
The ICR male mice, body weight 17-20g raises and stablized three days, ad lib, 50 mices are divided into 5 groups at random: blank (water 10ml/kg), positive (Presamine) and three various dose liquirtin groups, Presamine lumbar injection wherein, all the other respectively organize equal gastric infusion.Diameter 10cm is put into mice in experiment beginning administration in preceding 30 minutes then, in have 25 ℃, the 6min that swims in the high waterglass cylinder of 10cm, the dead time of record back 4min.Relatively whether the dead time of administration group has significant difference with blank group.The result is as shown in table 1, shows that the liquirtin small dose group compares with the blank group and have significant difference, gives the oral liquirtin of white mice, can significantly improve the dead time that mice is forced swimming test.
Table 1. heterogeneity is to forcing the comparison of mice non-swimming time influence
Group | Dosage | Number of animals | Dead time (S) | ???P |
Dosage group liquirtin low dose group in blank (water) miboplatin bright (injection) liquirtin high dose group liquirtin | ???10ml/kg ???20mg/kg ???20mg/kg ???10mg/kg ???5mg/kg | ???10 ???10 ???10 ???10 ???10 | ???210.1±12.5 ???141.16±17.3 ???178.35±21.84 ???188.55±21.36 ???194.10±15.42 | ? ??0.01 ??0.01 ??0.05 |
Experimental example 2, mouse tail suspension experiment
The result who adopts mouse tail suspension to test embodiment 1 verifies that experimental technique is as follows:
The ICR male mice, body weight 17-20g raises and stablized three days, ad lib, 30 mices are divided into 3 groups at random: blank (water 10ml/kg), positive (Presamine) and liquirtin group (20mg/kg).Presamine lumbar injection wherein, all the other respectively organize equal gastric infusion.Behind the administration 30min, hitch mice tail end 1cm place with nylon rope, its reversal of the natural order of things at 15cm place, distance bottom surface, is observed the absolute dead time in the mice 6min, relatively (10ml water/kg) whether the dead time exists significant difference to the administration group with blank group.The result is as shown in table 2, shows that liquirtin administration group (20mg/kg) compares with the blank group, can significantly shorten the absolute dead time of mice.
Table 2. liquirtin is to the influence of mouse tail suspension dead time
Group | Dosage | Number of animals | Dead time (S) | ????P |
Blank miboplatin bright (injection) liquirtin group | ???10ml/kg ???20mg/kg ???20mg/kg | ???10 ???10 ???10 | ???155.95±21.55 ???53.08±26.88 ???78.08±26.41 | ? ??0.001 ??0.001 |
Claims (1)
1, liquirtin prevents and/or treats application in the depression medicine in preparation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410004768 CN1272018C (en) | 2004-03-05 | 2004-03-05 | Application of liquorice glycoside in preparing drugs for preventing and/or treating depression |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410004768 CN1272018C (en) | 2004-03-05 | 2004-03-05 | Application of liquorice glycoside in preparing drugs for preventing and/or treating depression |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1663578A true CN1663578A (en) | 2005-09-07 |
CN1272018C CN1272018C (en) | 2006-08-30 |
Family
ID=35035006
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410004768 Expired - Fee Related CN1272018C (en) | 2004-03-05 | 2004-03-05 | Application of liquorice glycoside in preparing drugs for preventing and/or treating depression |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1272018C (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101032505B (en) * | 2006-04-17 | 2010-05-26 | 李超生 | Treatment medicine and healthy product including liquiritin |
CN101032504B (en) * | 2006-04-17 | 2010-05-26 | 李超生 | Application of liquiritin in medicines |
CN1961889B (en) * | 2005-11-09 | 2010-12-15 | 北京大学 | Application of isoliquiritigenin in preparation of medicament for preventing and/or treating depression |
JP2012062261A (en) * | 2010-09-15 | 2012-03-29 | Maruzen Pharmaceut Co Ltd | Composition for improving mood disorders |
-
2004
- 2004-03-05 CN CN 200410004768 patent/CN1272018C/en not_active Expired - Fee Related
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1961889B (en) * | 2005-11-09 | 2010-12-15 | 北京大学 | Application of isoliquiritigenin in preparation of medicament for preventing and/or treating depression |
CN101032505B (en) * | 2006-04-17 | 2010-05-26 | 李超生 | Treatment medicine and healthy product including liquiritin |
CN101032504B (en) * | 2006-04-17 | 2010-05-26 | 李超生 | Application of liquiritin in medicines |
JP2012062261A (en) * | 2010-09-15 | 2012-03-29 | Maruzen Pharmaceut Co Ltd | Composition for improving mood disorders |
Also Published As
Publication number | Publication date |
---|---|
CN1272018C (en) | 2006-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101185699B1 (en) | Usage of the plant of genus ampelopsis and extracts thereof for manufacture of medicament and functional food | |
CN101357136B (en) | Composition of traditional Chinese medicine effective constituent for preventing and treating diseased associated with cerebral ischemia injury | |
CN101732683A (en) | Chinese medicinal preparation for treating facial chloasma and preparation method thereof | |
CN1943618A (en) | Red sage root effective part standard extract and its preparing method and use | |
CN102014931B (en) | Use and preparation of paeoniflorin and the composition thereof | |
CN1272018C (en) | Application of liquorice glycoside in preparing drugs for preventing and/or treating depression | |
CN1140279C (en) | Blood-cleaning pill | |
CN101045137A (en) | Capsule for treating epilepsia and its preparing method | |
CN101152196A (en) | Application of notoginsen triterpenes and its monomer in preparing medicament for treating melancholia | |
CN101036708A (en) | Medicine composition for treatment of cardio-cerebralvascular disease | |
CN1686424A (en) | Medicinal composition containing scutellaria and bupleurum and its preparation method | |
CN103977336A (en) | Pharmaceutical composition with myocardial ischemia resisting effect and preparation method and application thereof | |
CN103520684B (en) | Traditional Chinese medicine compound for reducing blood sugar | |
CN103536879B (en) | A kind of pharmaceutical composition and preparation method for the treatment of diabetes | |
CN102274428B (en) | Pharmaceutical composition with effect on treating irritable bowel syndrome and preparation method and application thereof | |
CN1176690C (en) | Medicine for treating chronic nephritis | |
CN104800317A (en) | Chinese medicinal composition for preventing and treating chicken coccidiosis and preparation method | |
CN104825852A (en) | Tibetan medicine composition, preparation method and application thereof | |
CN116942771B (en) | Traditional Chinese medicine composition for treating coronary heart disease and application thereof | |
CN102908508B (en) | Medicinal composition for treating seborrheic alopecia and preparation method thereof | |
CN1211100C (en) | Compound combined medicine for giving up drug | |
CN1785988A (en) | Saflor yellow pigment rich in saflor yellow pigment B, its preparation method and use | |
CN102949681A (en) | Composition for preventing or treating colds, and its preparation method | |
CN101816708A (en) | Treat rheumatismal Chinese medicine composition and preparation method thereof | |
CN101991645A (en) | Preparation for treating coronary heart disease and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060830 Termination date: 20130305 |